As Grail finally leaves the Illumina nest, taking flight as a public, independent company for the first time, the cancer blood test developer said it would shed as much as 30% of its staff and narrow its focus to help it gain altitude on a single, primary objective.

Galera Therapeutics is shuttering, with the biotech’s board OK’ing a liquidation plan that whittles down the company’s workforce to just three people.

Metagenomi is editing its pipeline, choosing to seek a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis (ALS) activities in response to setbacks at a competitor.

Viracta Therapeutics is going all-in on its lymphoma program. The biotech responded to phase 2 data by throwing its resources behind a plan to file for a blood cancer approval in 2026, hitting pause on its solid tumor program and putting 23% of its staff out of a job in the process.

Evotec has set its sights on scrapping around 400 roles as the drug development services provider continues to battle tough market conditions.

As part of its national cancer moonshot efforts, the Biden administration aims to deliver $150 million in funding to developers of new technologies aimed at making tumor surgeries safer and more precise.

The Carlyle Group is finally closing in on its major medtech acquisition, following months of reports that it has been wooing companies looking to divest their divisions.

Eli Lilly has opened a $700 million R&D center in the Boston Seaport, boosting its RNA and DNA research capabilities and expanding its biotech-hosting Gateway Labs to the East Coast for the first time.

Only five months after securing a $100 million IPO, Boundless Bio is already laying off some employees as the precision oncology company grapples with low enrollment for a trial of its lead drug.

Psychopharmacology has pulled three articles about midstage clinical trial data assessing Lykos Therapeutics’ investigational MDMA candidate for treating post-traumatic stress disorder (PTSD). The journal cited “unethical conduct” at a research site as the reason for the retraction.